source
- Tyra Biosciences’ bladder cancer pill misses expected response rate in Phase 2 trialShares of Tyra Biosciences dropped about 20% after data from its Phase 2 study of a bladder cancer pill fell short of market expectations. The experimental drug, dabogratinib, is taken daily and t…
- Kura Oncology launches Caspian Therapeutics to develop menin-inhibitor diabetes drug with $50M fundingKura Oncology has spun out a new biotech called Caspian Therapeutics to focus on menin inhibitors for diabetes and other cardiometabolic diseases. The company’s lead candidate, code-named KO-7246,…